MN-VÄRDE-PARTNERS
12.10.2020 13:02:13 CEST | Business Wire | Press release
Värde Partners, a leading global alternative investment firm, today announced the promotion of Jon Fox to the role of President and Andy Lenk to the role of Deputy CEO, effective immediately. These appointments are the latest in a series of transition steps which previously included the appointment of Ilfryn Carstairs as Co-CEO and CIO and the promotions of Brad Bauer and Giuseppe Naglieri as Deputy CIOs.
“I’ve often said that transition is a process involving the entire firm and a number of leaders,” said George Hicks, Co-Founder and Co-CEO. “The appointments reflect the many contributions of Jon and Andy to the success and growth of the firm as well as the leadership experience and capabilities that they will bring to the years ahead.” Previously announced in July 2019, George intends to move to an Executive Chair role at the end of 2021.
Ilfryn Carstairs added, “These promotions are an important step in ensuring that we have the right senior leadership team for the next chapter at Värde. I’ve worked very closely with Jon and Andy for many years and I’m excited to see this elevation in their roles.”
In addition to the President and Deputy CEO roles, Värde announced promotions and role changes within the areas of Financial Services, Insurance, and Capital Markets:
- Elena Lieskovska, Partner, will head a new, dedicated Insurance business after leading this effort within the Financial Services team and previously leading specialty finance investing in Europe.
- Aneek Mamik, Senior Managing Director, will be promoted to Global Co-Head of Financial Services from his current role leading those investments in North America and Asia. He will oversee the global team with Partner Rick Noel.
- Craig Rydqvist, Senior Managing Director and Global Head of Capital Markets based in London, will join the Financial Services team to lead investments outside of North America.
- Missy Dolski, Managing Director, will be promoted to Global Head of Capital Markets from her current role as Head of Capital Markets for North America.
Commenting on these appointments, Deputy CIO Brad Bauer said, “We’re excited to announce these promotions which align proven leadership talent with significant areas of opportunity for our investors. These individuals represent the breadth and depth of talent we have in our investing teams and these promotions are well deserved in light of their contributions.”
Jon Fox is a Partner and the head of the New York office who joined the firm in 2013 in London. He has led the firm’s global Business Development and Investor Relations team, fund and product development, and also oversees Communications and Public Affairs. He is a member of the firm’s Investment Committee and Senior Leadership Committee and plays an important role in general management decisions. In 2018, Jon relocated from London to become the head of the firm’s New York office. He will maintain all existing leadership responsibilities as President and further develop Värde’s global industry relationships.
Jon holds a B.A. from the University of Colorado, an M.B.A. from Columbia Business School and serves on the boards of trustees of the Fire Department of New York (FDNY) Foundation and Oliver Scholars and on the Business Council of the Asia Society.
Andy Lenk joined the firm in 2001 and is a Partner in Minneapolis. As Global Head of Strategy and Portfolio Operations, he works closely with the Co-CEOs on all aspects of firm strategy, finance, talent and operations. He is a member of the firm’s Investment Committee, Senior Leadership Committee and the Enterprise Risk Management Committee. Andy has held many leadership roles for the firm including oversight and development of global Portfolio Operations, Capital Markets, Asset Management and the firm’s Finance and Operations functions. Earlier in his career at Värde, Andy worked in investing teams in both the U.S. and Europe.
Andy received a B.B.A. in Accounting from the University of Wisconsin-Madison and an M.B.A. from the University of Michigan. He is a CPA (inactive).
About Värde Partners
Värde Partners is a leading global alternative investment firm with roots in credit and distressed. Founded in 1993, the firm has invested more than $75 billion since inception and manages over $14 billion on behalf of a global investor base. The firm’s investments span corporate and traded credit, real estate and mortgages, private equity and direct lending. Värde employs more than 300 professionals worldwide with offices in Minneapolis, New York, London, Singapore and other cities in Asia and Europe. For more information, please visit www.varde.com
.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201012005330/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
